Patents Assigned to Daiichi Sankyo Company, Limited
  • Patent number: 11806339
    Abstract: The present invention provides a medicament comprising a compound represented by general formula (1) which has Axl inhibitory activity, and an EGFR tyrosine kinase inhibitor in combination, and a method for treating cancer using this combination. The present invention provides an excellent medicament and method for treating cancer which is highly effective for inhibiting resistance to an EGFR tyrosine kinase inhibitor in cancer treatment, and causes less adverse reactions such as weight loss.
    Type: Grant
    Filed: May 2, 2022
    Date of Patent: November 7, 2023
    Assignee: Daiichi Sankyo Company, Limited
    Inventor: Takeshi Jimbo
  • Publication number: 20230348522
    Abstract: The present invention provides a crystalline 2,4-bridged common intermediate useful for producing a plurality of ENA monomers, a method for stereoselectively producing the intermediate, and a method for efficiently producing ENA monomers using the intermediate.
    Type: Application
    Filed: October 16, 2020
    Publication date: November 2, 2023
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Makoto Michida, Kazutoshi Ukai, Yuzo Abe, Moe Matsumoto, Makoto Yamaoka, Kei Kurahashi
  • Publication number: 20230348616
    Abstract: An antibody that can be used as an anti-tumor agent and an anti-tumor agent comprises a molecule containing such an antibody. Such an antibody or a binding fragment thereof comprises: a heavy chain CDRH1 consisting of SEQ ID NO: 54, a heavy chain CDRH2 consisting of SEQ ID NO: 55, a heavy chain CDRH3 consisting of SEQ ID NO: 56, a light chain CDRL1 consisting of SEQ ID NO: 57 or a light chain CDRL1 consisting of an amino acid sequence derived from SEQ ID NO: 57 in which amino acid 7 is W and/or amino acid 8 is K, a light chain CDRL2 consisting of SEQ ID NO: 58, and a light chain CDRL3 consisting of SEQ ID NO: 59 or a light chain CDRL3 consisting of an amino acid sequence derived from SEQ ID NO: 59 in which amino acid 2 is A or S.
    Type: Application
    Filed: March 29, 2021
    Publication date: November 2, 2023
    Applicants: MIE UNIVERSITY, DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Hiroshi SHIKU, Yasushi AKAHORI, Kento TANAKA, Ayaka YATSU, Junya ICHIKAWA, Toshiaki OHTSUKA, Shiho KOZUMA, Ryuji HASHIMOTO, Makiko NAKAYAMA, Naoya SHINOZAKI, Kensuke NAKAMURA, Ichiro WATANABE, Shinji FURUZONO
  • Publication number: 20230340118
    Abstract: An object of the present invention is to provide a novel anti-CD147 antibody exhibiting potent antitumor efficacy and having excellent safety. Another object of the present invention is to provide a pharmaceutical product comprising such an antibody. Another object of the present invention is to provide a method for treating tumors using the antibody or the pharmaceutical product, for example. The present invention provides a CD147-specific antibody that activates CD147 and exhibits high antitumor efficacy. The present invention provides the anti-CD147 antibody that exhibits high antitumor efficacy independent of effector functions. The present invention provides a pharmaceutical composition comprising such an anti-CD147 antibody. The present invention provides a method for treating tumors using such an anti-CD147 antibody and/or pharmaceutical composition.
    Type: Application
    Filed: May 10, 2023
    Publication date: October 26, 2023
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Keisuke FUKUCHI, Kayoko NANAI, Masato AMANO, Kozo YONEDA, Yusuke TOTOKI, Shoji YAMAMOTO
  • Patent number: 11795236
    Abstract: As an antitumor drug which is excellent in terms of antitumor effect and safety and has an excellent therapeutic effect, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-HER2 antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-(CH2)n2-C(?O)— wherein the anti-HER2 antibody is connected to the terminal L1, and the antitumor compound is connected to the carbonyl group of the —(CH2)n2-C(?O)— moiety with the nitrogen atom of the amino group at position 1 as the connecting position
    Type: Grant
    Filed: September 13, 2018
    Date of Patent: October 24, 2023
    Assignee: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Hiroyuki Naito, Yusuke Ogitani, Takeshi Masuda, Takashi Nakada, Masao Yoshida, Shinji Ashida, Koji Morita, Hideki Miyazaki, Yuji Kasuya, Ichiro Hayakawa, Yuki Abe
  • Publication number: 20230330243
    Abstract: A pharmaceutical product for administration of an anti HER2 antibody-drug conjugate in combination with an ATR inhibitor is provided. The anti-HER2 antibody-drug conjugate is an antibody-drug conjugate in which a drug linker represented by the following formula (wherein A represents the connecting position to an antibody) is conjugated to an anti-HER2 antibody via a thioether bond.
    Type: Application
    Filed: June 23, 2021
    Publication date: October 19, 2023
    Applicants: Daiichi Sankyo Company, Limited, AstraZeneca UK Limited
    Inventors: Jerome Thomas METTETAL, II, Stephen Thomas DURANT, Azadeh Cheraghchi Bashi ASTANEH, Alan Yin Kai LAU, Yann WALLEZ
  • Publication number: 20230331700
    Abstract: An object of the present invention is to provide a compound having an anti-inflammatory activity or a pharmacologically acceptable salt thereof. The solution of the present invention is a compound of general formula (1) or a pharmacologically acceptable salt thereof. wherein the symbols in the formula are defined below: A: e.g., Benzene, E: e.g., —CH2—, G: e.g., a 5-membered aromatic heterocyclic ring, X: e.g., cyclohexane, J: e.g., a 5-membered aromatic heterocyclic ring, Y: e.g., a phenyl group, R1, R2, R3: e.g., a halogen atom, R4: e.g., a C1-C6 alkyl group, R5: e.g., a hydrogen atom, R6a, R6b, R6c, R6d: e.g., a hydrogen atom, R7: e.g., a hydrogen atom, R8: e.g., a hydrogen atom, n1, n2, n3: e.g., 1.
    Type: Application
    Filed: November 21, 2022
    Publication date: October 19, 2023
    Applicant: Daiichi Sankyo Company, Limited
    Inventors: Toru Taniguchi, Osamu Iwamoto, Keiji Saito, Katsuyoshi Nakajima, Yasuyuki Ogawa, Nobuya Kurikawa, Seiko Nagata, Kaori Ito, Eriko Kioi
  • Publication number: 20230330248
    Abstract: [Problem] It is desired to develop an antibody-drug conjugate capable of being systemically administered and delivering a STING agonist specifically to a target cells or organ (for example, a tumor lesion), and a therapeutic agent and/or therapeutic method using the antibody-drug conjugate for diseases related to STING agonist activity, for example, diseases (for example, cancers) to which immunostimulation therapy can be applied. [Solution] The present invention provides a novel antibody-CDN derivative conjugate which can be systemically administered and exhibits an antitumor effect against an antigen-expressing tumor.
    Type: Application
    Filed: March 5, 2021
    Publication date: October 19, 2023
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Masayuki ISHIZAKI, Osamu SUZUKI, Mariko KYUTOKU, Hiroshi YUKIURA, Kyoko HARA, Masataka CHIHARA, Takafumi OTSUKA, Teiji WADA
  • Publication number: 20230293714
    Abstract: A pharmaceutical composition, wherein an anti-HER2 antibody-drug conjugate in which a drug-linker represented by the following formula (wherein A represents a connecting position to an anti-HER2 antibody) is conjugated to the anti-HER2 antibody via a thioether bond, and a HER dimerization inhibitor are administered in combination, and/or a method of treatment, wherein the anti-HER2 antibody-drug conjugate and a HER dimerization inhibitor are administrated in combination to a subject.
    Type: Application
    Filed: July 19, 2021
    Publication date: September 21, 2023
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventor: Yasuki KAMAI
  • Publication number: 20230287119
    Abstract: The present invention provides a novel antibody binding to human CD3, and a molecule having antigen binding activity that includes the antibody. The present invention provides a novel antibody binding to human CD3, a molecule having antigen binding activity that includes the antibody, and a pharmaceutical composition having cytotoxic activity that includes the antibody or the molecule as an active ingredient.
    Type: Application
    Filed: April 3, 2023
    Publication date: September 14, 2023
    Applicant: Daiichi Sankyo Company, Limited
    Inventors: Tohru TAKAHASHI, Chigusa YOSHIMURA, Shiho KOZUMA, Kensuke NAKAMURA, Chikako SUZUKI, Junya ICHIKAWA
  • Publication number: 20230287121
    Abstract: A novel antibody that can be used as an anti-tumor agent and an anti-tumor agent that comprises, as an active ingredient, a molecule containing such an antibody.
    Type: Application
    Filed: May 16, 2023
    Publication date: September 14, 2023
    Applicants: MIE UNIVERSITY, DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Hiroshi SHIKU, Yasushi AKAHORI, Kento TANAKA, Ayaka YATSU, Junya ICHIKAWA, Toshiaki OHTSUKA, Shiho OKZUMA, Ryuji HASHIMOTO, Makiko NAKAYAMA, Naoya SHINOZAKI, Kensuke NAKAMURA, Ichiro WATANABE, Shinji FURUZONO
  • Publication number: 20230277679
    Abstract: A method for producing an antibody-drug conjugate composition, comprising: (i) a step of reacting an antibody with a reducing agent to obtain an antibody having thiol groups; then (ii) a step of reacting drug-linker intermediates with the antibody having thiol groups obtained in the step (i), wherein the step (i) is carried out until the composition ratio of the antibody having four heavy-light interchain thiols and the composition ratio of the antibody having four heavy-heavy interchain thiols reach a steady value.
    Type: Application
    Filed: July 16, 2021
    Publication date: September 7, 2023
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Hitoshi SATO, Yuka SASORI, Daisuke FUKATSU
  • Publication number: 20230270870
    Abstract: The present disclosure relates to the field of pharmaceutical preparations, dosage regimens, and administration of an antibody-drug conjugate (ADC). More specifically, the ADC is composed of an anti-trophoblast cell surface antigen 2 (TROP2) antibody connected via a linker to an anticancer agent, such as topoisomerase I inhibitor.
    Type: Application
    Filed: May 28, 2020
    Publication date: August 31, 2023
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Yutaka NOGUCHI, Tomonari YAMASHITA, Daisuke OKAJIMA, Takuma IGUCHI, Satoru YASUDA, Jonathan GREENBERG
  • Publication number: 20230265431
    Abstract: Provided is a short-chain guide RNA that is able to induce site-specific editing even when only a small number of nucleotides is attached to the target recognition site. The guide RNA includes a first oligonucleotide that identifies the target RNA, and a second oligonucleotide that links to the 3? end of the first oligonucleotide. The first oligonucleotide contains: a target-corresponding nucleotide residue that corresponds to an adenosine residue in the target RNA; an oligonucleotide of 15 to 30 residues that links to the 5? end of the target-corresponding nucleotide residue and that has a base sequence complementary to the target RNA; and an oligonucleotide of 3 or 4 residues that links to the 3? end of the target-corresponding nucleotide residue and that has a base sequence complementary to the target RNA. The second oligonucleotide contains 2 to 24 nucleotide residues, and induces site-specific editing of the target RNA.
    Type: Application
    Filed: March 22, 2023
    Publication date: August 24, 2023
    Applicants: FUKUOKA UNIVERSITY, DAIICHI SANKYO COMPANY, LIMITED
    Inventor: Masatora FUKUDA
  • Publication number: 20230257767
    Abstract: The present invention provides an approach to enhancing the production of a foreign protein serving as a protein-based pharmaceutical product in host cells such as cultured cells derived from a mammal. The present invention provides transformed cells having a novel Hspa5 gene promoter, and a method for secreting and producing a foreign protein at high levels using the transformed host cells.
    Type: Application
    Filed: January 12, 2023
    Publication date: August 17, 2023
    Applicant: Daiichi Sankyo Company, Limited
    Inventors: Kenji Masuda, Koichi Nonaka, Hiroki Tanemura
  • Publication number: 20230257368
    Abstract: An object of the present invention is to provide an industrially useful and novel process for producing a 1,3-benzodioxole derivative, with high yield and few impurities, including a novel chlorination reaction of a benzene ring. In the novel process for producing a 1,3-benzodioxole derivative, it has been found that an industrially useful and novel chlorination reaction of a benzene ring is conducted by using sulfuryl chloride with high yield and few impurities. Based on the finding, the invention has been accomplished.
    Type: Application
    Filed: July 7, 2021
    Publication date: August 17, 2023
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Tsuyoshi UEDA, Yuji KAIYA, Takahisa UCHIDA, Makoto IMAI
  • Publication number: 20230226205
    Abstract: It is an object of the present invention to provide an antibody binding to CDH6 and having internalization activity, an antibody-drug conjugate of the antibody and a drug having antitumor activity, a pharmaceutical product comprising the antibody-drug conjugate and having therapeutic effects on a tumor, a method for treating a tumor using the antibody, the antibody-drug conjugate or the pharmaceutical product, and the like. The present invention provides an anti-CDH6 antibody having internalization activity, an antibody-drug conjugate of the antibody and a drug having antitumor activity, a pharmaceutical product comprising the antibody or the antibody-drug conjugate, and a method for treating a tumor.
    Type: Application
    Filed: July 26, 2022
    Publication date: July 20, 2023
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Atsuko SAITO, Tsuyoshi HIRATA, Kensuke NAKAMURA
  • Publication number: 20230212306
    Abstract: The present invention provides a pharmaceutical composition comprising an antibody which binds specifically to human TLR7 or monkey TLR7 and does not bind to mouse TLR7 or rat TLR7, and has an activity of inhibiting a function of human TLR7 or monkey TLR7, and the like.
    Type: Application
    Filed: December 27, 2022
    Publication date: July 6, 2023
    Applicants: Daiichi Sankyo Company, Limited, The University of Tokyo
    Inventors: Kensuke Miyake, Yusuke Murakami, Yuji Motoi, Atsuo Kanno, Toshiyuki Shimizu, Umeharu Ohto, Takaichi Shimozato, Atsushi Manno, Takashi Kagari, Jun Ishiguro, Kensuke Nakamura, Takashi Isobe
  • Publication number: 20230203132
    Abstract: The present invention provides a novel peptide that has an amino acid sequence represented by SEQ ID NO: 18, and binds to an active protease but does not bind to a pro-protease.
    Type: Application
    Filed: November 21, 2022
    Publication date: June 29, 2023
    Applicant: Daiichi Sankyo Company, Limited
    Inventors: Hidenori Yano, Daisuke Nishimiya, Ryuji Hashimoto, Yoichi Niitsu
  • Patent number: 11667642
    Abstract: Provided is a novel and industrially useful method for producing a 3,6-disubstituted imidazo[1,2-b]pyridazine derivative. The present invention provides a method for producing a 3,6-disubstituted imidazo[1,2-b]pyridazine derivative, which uses 6-fluoroimidazo[1,2-b]pyridazine as a starting material, while using an aromatic substitution reaction that utilizes C—H activation by means of palladium.
    Type: Grant
    Filed: February 1, 2021
    Date of Patent: June 6, 2023
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Ryoji Koike, Yoshifumi Hachisu, Takafumi Kitawaki, Shohei Shiraishi